TIDMROQ

RNS Number : 5782P

Roquefort Investments PLC

20 October 2021

20 October 2021

Roquefort Investments plc

("Roquefort Investments" or the "Company")

Board Changes

Roquefort Investments ( LSE:ROQ ), the investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector , announces the appointment of Mr Mark Freeman as a non-executive director and the resignation of Mr Glenn Whiddon as non-executive director with effect from today.

Mr Freeman (aged 46) is a Chartered Accountant and has more than 25 years' experience in corporate finance and the public markets, with a focus on project development. Mr Freeman is a graduate of the University of Western Australia with a Bachelor of Commerce with a double major in Banking & Finance and Accounting as well as holding a Graduate Diploma in Applied Finance with a major in Investment Analysis from the Securities Institute of Australia. He has experience in strategic planning, business development, acquisitions and mergers, project commercialisation, project development and general management. Mr Freeman is currently a director of Pursuit Minerals Ltd (ASX:PUR), Calima Energy Ltd (ASX:CE1) and Grand Gulf Energy Ltd (ASX:GGE).

In addition, Mr Freeman is currently a director of Lyramid Limited ("Lyramid"). It is intended that Mr Freeman will retain his position as one of the two Australian resident directors required to be appointed to the Board of Lyramid after the proposed acquisition of Lyramid has completed.

Stephen West, Executive Chairman, commented:

"As we work towards completion of the Lyramid transaction, it is important to have a financially oritentated Australian resident director with public markets experience to assist the Company going forward. We are therefore delighted that Mark Freeman has agreed to join the Company as a non-executive director given his proven track record and experience in this regard. I would like to thank Glenn Whiddon for working with us from the formation of Roquefort Investments up to this transformational stage for the Company.

The Board is focused on completing the Lyramid transaction and the RTO process and we look forward to providing a further update on this shortly."

Enquiries:

 
 Roquefort Investments plc 
                                      +44 (0)20 3290 
 Stephen West (Chairman)                        9339 
 Optiva Securities Limited (Joint 
  Broker) 
                                     +44 (0) 20 3411 
 Christian Dennis                               1881 
 

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

LEI: 254900P4SISIWOR9RH34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFFEFIUEFSEIS

(END) Dow Jones Newswires

October 20, 2021 02:00 ET (06:00 GMT)

Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Roquefort Therapeutics.
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Roquefort Therapeutics.